Wall Street Zen Downgrades Teleflex (NYSE:TFX) to Sell

Teleflex (NYSE:TFX) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

A number of other equities analysts have also recently issued reports on TFX. BMO Capital Markets started coverage on Teleflex in a report on Wednesday, July 8th. They issued an “outperform” rating and a $159.00 price objective for the company. Bank of America raised Teleflex from an “underperform” rating to a “neutral” rating and set a $135.00 price objective on the stock in a report on Monday, April 13th. Weiss Ratings reissued a “sell (d)” rating on shares of Teleflex in a report on Wednesday, June 24th. UBS Group began coverage on Teleflex in a research report on Tuesday, July 28th. They issued a “neutral” rating and a $145.00 target price for the company. Finally, Truist Financial reaffirmed a “hold” rating and issued a $143.00 target price (up from $135.00) on shares of Teleflex in a research note on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Teleflex currently has a consensus rating of “Hold” and an average target price of $148.90.

Teleflex Stock Performance

NYSE TFX opened at $136.72 on Friday. Teleflex has a 52-week low of $100.18 and a 52-week high of $139.67. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.03 and a current ratio of 2.55. The company has a market capitalization of $6.05 billion, a P/E ratio of -6.00, a P/E/G ratio of 1.02 and a beta of 0.81. The company has a fifty day moving average of $130.96 and a 200-day moving average of $121.46.

Teleflex (NYSE:TFX) last announced its earnings results on Thursday, May 7th. The medical technology company reported $1.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.21 by $0.18. The company had revenue of $548.30 million during the quarter, compared to analyst estimates of $536.91 million. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. The firm’s quarterly revenue was up 32.3% compared to the same quarter last year. During the same period in the previous year, the business earned $1.44 earnings per share. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. As a group, equities research analysts predict that Teleflex will post 6.7 EPS for the current fiscal year.

Institutional Investors Weigh In On Teleflex

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Janus Henderson Group PLC grew its position in Teleflex by 1.1% during the 1st quarter. Janus Henderson Group PLC now owns 4,291,311 shares of the medical technology company’s stock worth $513,281,000 after acquiring an additional 45,199 shares during the last quarter. AQR Capital Management LLC lifted its position in Teleflex by 478.1% in the third quarter. AQR Capital Management LLC now owns 2,366,131 shares of the medical technology company’s stock valued at $287,603,000 after purchasing an additional 1,956,811 shares during the last quarter. State Street Corp lifted its position in Teleflex by 1.5% in the fourth quarter. State Street Corp now owns 1,478,776 shares of the medical technology company’s stock valued at $180,470,000 after purchasing an additional 22,111 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Teleflex by 0.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,250,665 shares of the medical technology company’s stock valued at $152,630,000 after purchasing an additional 5,051 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Teleflex by 10.6% during the fourth quarter. Geode Capital Management LLC now owns 985,684 shares of the medical technology company’s stock valued at $120,312,000 after purchasing an additional 94,679 shares during the period. Institutional investors own 95.62% of the company’s stock.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.